NCT00730925View on ClinicalTrials.gov

Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

January 31, 2012

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

BIBW2992

tablet BIBW high dose

DRUG

BIBW2992 + paclitaxel

tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly

Trial Locations (7)

Unknown

1200.41.32003 Boehringer Ingelheim Investigational Site, Antwerp

1200.41.32007 Boehringer Ingelheim Investigational Site, Charleroi

1200.41.32001 Boehringer Ingelheim Investigational Site, Jette

1200.41.32011 Boehringer Ingelheim Investigational Site, Leuven

1200.41.32008 Boehringer Ingelheim Investigational Site, Liège

1200.41.32006 Boehringer Ingelheim Investigational Site, Namur

1200.41.34001 Boehringer Ingelheim Investigational Site, Badalona (Barcelona)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00730925 - Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients | Biotech Hunter | Biotech Hunter